FDA approves Sanofi's Jevtana for prostate cancer; Amgen looks for acquisitions;

 @FierceBiotech: EXCLUSIVE: Pfizer plans to move fast on rare disease pacts. Story | Follow @FierceBiotech

 @JohnCFierce: GW is developing Sativex (with Otsuka) for cancer pain in the US; significantly more lucrative than the MS approvals it's getting in Europe. | Follow @JohnCFierce

> The FDA has approved Sanofi-Aventis' prostate cancer injection Jevtana (cabazitaxel). The drug is used combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen. Sanofi release

> Amgen is "aggressively" looking at acquisitions, particularly opportunities for international expansion, Chief Executive Kevin Sharer said. Report

> Genzyme has entered into an agreement with Goldman Sachs to repurchase $1 billion of Genzyme common stock. Genzyme release

And Finally... Women who drink tea have an increased risk of developing Rheumatoid Arthritis compared with those who drink none, according to Georgetown University Medical Center study. Release

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.